NDA 210864 · Lupin
Sesquient
Fosphenytoin Sodium · Intravenous
DiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Nov 5, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
4 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- SESQUIENT · FOSPHENYTOIN SODIUM EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) · SOLUTION, INTRAVENOUS · Discontinued
- SESQUIENT · FOSPHENYTOIN SODIUM EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fosphenytoin" as an intervention, any sponsor and status, largest first.
- Established Status Epilepticus Treatment TrialPivotal-lookingCompleted
University of VirginiaAcademic, hospital or other
NCT01960075 · 478 participants · Start Oct 2015 · Primary completion Feb 2019
Drug: Fosphenytoin; Levetiracetam and 1 more · For: Benzodiazepine Refractory Status Epilepticus
Sites: Tucson, Arizona; Los Angeles, California; Sacramento, California · 65 sites in all
- Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status EpilepticusPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01870024 · 434 participants · Start Jun 26, 2013 · Primary completion Feb 23, 2018
Drug: Clonazepam; Fosphenytoin and 2 more · For: Status Epilepticus; Epilepsy
Sites: Paris, France
Center for International Blood and Marrow Transplant ResearchResearch network
NCT06859424 · 358 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 2028
Drug: Conditioning Regimen A; Conditioning Regimen B and 12 more · For: AML (Acute Myelogenous Leukemia); Acute Lymphoid Leukemia (ALL); Acute Leukemia (Category) and 8 more
Sites: Birmingham, Alabama; Duarte, California; Palo Alto, California · 13 sites in all
- IV Keppra in the Emergency Department for Prevention of Early Recurrent SeizuresPivotal-lookingCompleted
Emory UniversityAcademic, hospital or other
NCT00510783 · 158 participants · Start Jul 2007 · Primary completion Dec 2008
Drug: Keppra; Fosphenytoin and 1 more · For: Tonic-clonic Seizure
Sites: Atlanta, Georgia
Aatif HusainAcademic, hospital or other
NCT01458522 · 74 participants · Start May 2012 · Primary completion Jul 2014
Drug: fPHT; LCM · For: Nonconvulsive Seizures
Sites: Pasadena, California; New Haven, Connecticut; Atlanta, Georgia · 11 sites in all
- The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status EpilepticusCompleted
Dhaka Medical CollegeAcademic, hospital or other
NCT06403150 · 62 participants · Start May 15, 2023 · Primary completion Aug 31, 2024
Drug: Levetiracetam Injection; Fosphenytoin Injection · For: Status Epilepticus
Sites: Dhaka, Bangladesh
Thomas Jefferson UniversityAcademic, hospital or other
NCT00774306 · 52 participants · Start Apr 2009 · Primary completion Jun 2012
Drug: phenytoin; valproate and 1 more · For: Subarachnoid Hemorrhage
University of CincinnatiAcademic, hospital or other
NCT00618436 · 52 participants · Start Aug 2007 · Primary completion Sep 2009
Drug: Levetiracetam; Phenytoin · For: Traumatic Brain Injury; Subarachnoid Hemorrhage
Sites: Cincinnati, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
Kapur J, Elm J, Chamberlain JM, et al. · N Engl J Med 2019 · Comparative Study, Multicenter Study
- Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
Chamberlain JM, Kapur J, Shinnar S, et al. · Lancet 2020 · Multicenter Study, Randomized Controlled Trial
- Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society.
Frontera JA, Gilmore EJ, Johnson EL, et al. · Neurocrit Care 2024 · Systematic Review, Practice Guideline
- Guidelines for Seizure Prophylaxis in Patients Hospitalized with Nontraumatic Intracerebral Hemorrhage: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society.
Frontera JA, Rayi A, Tesoro E, et al. · Neurocrit Care 2025 · Systematic Review, Practice Guideline
- Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Szaflarski JP, Sangha KS, Lindsell CJ, et al. · Neurocrit Care 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- IV Fosphenytoin for Acute Trigeminal Neuralgia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Noro S, Hatayama T, Iwai Y, et al. · Neurology 2026 · Multicenter Study, Randomized Controlled Trial
Sponsor: Lupin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.